OTCM
BOEUF
Market cap1.46bUSD
Sep 30, Last price
23.00USD
Name
Bonesupport Holding AB
Chart & performance
P/E
105.92
P/S
12.82
EPS
2.17
Div yield, %
—
Shrs. gr., 5y
2.48%
Rev. gr., 5y
45.38%
Revenues
1.17b
+30.70%
Net income
142m
+6.28%
CFO
221m
+236.53%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bonesupport Holding AB (publ) is an orthobiologics company that specializes in the development and commercialization of injectable bioceramic bone graft substitutes. These products are utilized for treating bone voids and are available internationally, including in Europe and North America. Among its key offerings are CERAMENT Bone Void Filler, a synthetic, injectable, moldable, and drillable solution comprising hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol. Additionally, the company provides CERAMENT G, an injectable ceramic bone graft substitute infused with gentamicin, and CERAMENT V, a synthetic bone void filler containing vancomycin. Bonesupport is also advancing preclinical product candidates focused on promoting bone regrowth. These future solutions are being developed for applications such as trauma, revision arthroplasty, chronic osteomyelitis, oncology, and bone and foot infections related to diabetes. Founded in 1999, the company maintains its headquarters in Lund, Sweden.
Key people
Chief Executive Officer · since 2018
Hakan Johansson
Chief Financial Officer · since 2018
Johan Olsson
Chief Operating Officer
Fergus MacLeod
General Manager, Executive Vice President - Commercial Operations EUROW · since 2019
Annelie Aava Vikner
Executive Vice President Marketing & Communications · since 2019
Patrick O'Donnell
General Manager & Executive Vice President Commercial Operations North America
Michael Roth
Executive Vice President - Commercial Operations North America, General Manager · since 2020
Simon Cartmell
Director · since 2018
Independent Director · since 2019
Independent Director · since 2010
Headquarters & legal address
Scheelevägen 19 A
Lund, M 223 70
SE
Lund, M 223 70
SE
Address
Scheelevagen 19 A
Lund, M 223 70
SE
Lund, M 223 70
SE
Previous name
Goldcup 5429 AB
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||